Just wondering if we could take two birds with one stone here: Zynerba has just started its Phase 2 trial for Zygel, a synthetic cannabidiol formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin to target autism spectrum disorder..(fragile X syndrome) ....you could have 'em settled and with a peachy skin. BTXs would certainly be first covered by insurance and ready for prescription, it'd be pair to multi-indications targeting blockbusters of the kind of Humira and Cosentyx.
https://clinicaltrials.gov/ct2/show/NCT03802799?term=zynerba&rank=1
do not advertise external links/companies/news/216010/zynerba-pharmaceuticals-launches-phase-2-trial-of-zygel-in-autism-spectrum-disorder-216010.html
Botanix Takeover, page-17
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 30.5¢ | $1.502M | 4.765M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 189068 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 535424 | 6 |
View Market Depth
| Last trade - 16.10pm 21/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
